Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

NCT00170573 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Caelyx

Sponsor

North Eastern German Society of Gynaecological Oncology